Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 211 to 225 of 243 results for maternity

  1. The AutoPulse non-invasive cardiac support pump for cardiopulmonary resuscitation (MIB18)

    NICE has developed a Medtech Innovation Briefing (MIB) on the AutoPulse non-invasive cardiac support pump for cardiopulmonary resuscitation

  2. The Oncentra Prostate v4.x for ultrasound‑guided real‑time HDR brachytherapy in men with localised prostate cancer (MIB16)

    NICE has developed a Medtech Innovation Briefing (MIB) on the Oncentra Prostate v4.x ultrasound-guided real-time HDR brachytherapy in men with localised

  3. Gastro-oesophageal reflux in children and young people (QS112)

    This quality standard covers managing symptoms of reflux (regurgitation or bringing up feeds) in babies, children and young people (under 18). It also covers diagnosing and managing gastro-oesophageal reflux disease (also called GORD), which is more severe reflux and heartburn. It describes high-quality care in priority areas for improvement.

  4. The SpyGlass direct visualisation system for diagnostic and therapeutic procedures during endoscopy of the biliary system (MIB21)

    NICE has developed a Medtech Innovation Briefing (MIB) on the SpyGlass direct visualisation system for diagnostic and therapeutic procedures during endoscopy of

  5. Peptest for diagnosing gastro‑oesophageal reflux (MIB31)

    NICE has developed a medtech innovation briefing (MIB) on Peptest for diagnosing gastro-oesophageal reflux

  6. PLGF-based testing to help diagnose suspected preterm pre-eclampsia (HTG630)

    Evidence-based recommendations on placental growth factor (PLGF)-based testing to help diagnose suspected preterm pre-eclampsia. The tests are: DELFIA Xpress PLGF 1-2-3, DELFIA Xpress sFlt-1/PLGF 1-2-3 ratio, Elecsys immunoassay sFlt-1/PLGF ratio, Triage PLGF Test.

  7. Plasma EGFR mutation tests for adults with locally advanced or metastatic non-small-cell lung cancer (MIB137)

    NICE has developed a medtech innovation briefing (MIB) on plasma EGFR mutation tests for adults with locally advanced or metastatic non-small-cell lung cancer .

  8. The SENSIMED Triggerfish contact lens sensor for continuous 24-hour recording of ocular dimensional changes in people with or at risk of developing glaucoma (MIB14)

    NICE has developed a Medtech Innovation Briefing (MIB) on the SENSIMED Triggerfish contact lens sensor for continuous 24-hour recording of ocular dimensional

  9. Video laryngoscopes to help intubation in people with difficult airways (MIB167)

    NICE has developed a medtech innovation briefing (MIB) on video laryngoscopy to help intubation in people with difficult airways .

  10. The OraQuick HCV point‑of‑care test for rapid detection of hepatitis C virus antibodies (MIB24)

    NICE has developed a medtech innovation briefing (MIB) on the OraQuick HCV point-of-care test for rapid detection of hepatitis C virus antibodies

  11. The Juxta CURES adjustable compression system for treating venous leg ulcers (MIB25)

    NICE has developed a medtech innovation briefing (MIB) on the Juxta CURES adjustable compression system for treating venous leg ulcers

  12. LARS for reconstructing damaged intra-articular cruciate knee ligaments (MIB30)

    NICE has developed a medtech innovation briefing (MIB) on LARS for reconstructing damaged intra-articular cruciate knee ligaments

  13. Mechanical thrombectomy devices for acute ischaemic stroke (MIB153)

    NICE has developed a medtech innovation briefing (MIB) on mechanical thrombectomy devices for acute ischaemic stroke .

  14. Oxyzyme and Iodozyme 2-layer hydrogel wound dressings with iodine for treating chronic wounds (MIB11)

    NICE has developed a Medtech Innovation Briefing (MIB) on Oxyzyme and Iodozyme 2-layer hydrogel wound dressings with iodine for treating chronic wounds

  15. Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19 (TA878)

    Evidence-based recommendations on nirmatrelvir plus ritonavir (Paxlovid), sotrovimab (Xevudy) and tocilizumab (RoActemra) for treating COVID-19.